Early predictors of response to treatment in patients with chronic hepatitis C

Journal of Hepatology, Supplement

Volumn 31, Issue 1, 1999, Pages 237-243

  Civeira, Maria Pilar ^a   Prieto, Jesus ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Predictors of response; Sustained response; Viraemia

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; CONSENSUS INTERFERON; INTERFERON; LYMPHOBLAST INTERFERON; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RESPONSE; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD;

EID: 0033430353     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(99)80409-7     Document Type: Conference Paper

References (41)

1. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O et al. Ribavirin enhances the efficacy but not the adverse effects of Interferon in chronic hepatitis C. J Hepatol 1997: 26: 961-966.
2. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C et al. Long-term histologie improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-or therapy. Ann Intern Med 1997: 127: 875-881.
3. Manabe N, Chevallier M, Chossegros P, Causse X, Guerret S, Trépo C et al. Interferon-a2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: A quantitative histological évaluation. Hepatology 1993: 18: 1344-1349.
4. Serfaty L, Aumaitre H, Chazouillères O, Bonnand AM, Rosmorduc O, Poupon RE et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998: 27: 1435-1440.
5. International Interferon-or Hepatocellular Carcinoma Study Group. Effect of interferon-ot on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998: 351: 1535-1539.
6. Gavier B, Martinez-Gonzâlez MA, Riezu-Boj JI, Lasarte JJ, Garcia N, Civeira MP et al. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 1997: 113: 1647-1653.
7. Chemello L, Cavalletto L, Casarin C, Bonetti P, Bernardinello E, Pontisso P et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-a in chronic hepatitis C. Ann Intern Med 1996: 124: 1058-1060.
8. Aiyama T, Yoshioka K, Takayanagi M, Iwata K, Okumura A, Kakumu S. Serum HCV RNA titer at the end of interferon therapy predicts the long-term outcome of treatment. J Hepatol 1995: 23: 497-502.
9. Saracco G, Borghesio E, Mesina P, Solinas A, Spezia C, Macor F et al. Prolonged treatment (2 years) with different doses (3 vs 6 MU) of interferon a-2b for chronic hepatitis type C. J Hepatol 1997: 27: 56-62.
10. Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Baiart LA, Dienstag JL et al. Response to higher doses of interferon alpha2b in patients with chronic hepatitis C: A randomized multicenter trial. Hepatology 1996: 24: 1034-1040.
11. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 1995: 22: l OSO1056.
12. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N et al. Liver, pancreas, and biliary tract. Gastroenterology 1997: 113:558-566.
13. Martinot-Peignoux M, Boyer N, Pouteau M, Castelnau C, Giuily N, Duchatelle V et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998: 29: 214-223.
14. Camps J, Crisôstomo S, Garcia-Granero M, Riezu-Boj JI, Civeira MP, Prieto J. Prediction of the response of chronic heptitis C to Interferon alpha: a statistical analysis of pretreatment variables. Gut 1993: 34: 1714-1717.
15. Conjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of a sustained beneficial response to interferon alpha therapy in chronic hepatitis C. Hepatology 1995: 22: 1326-1329.
16. Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype Ib hepatitis C virus infection. Hepatology 1997: 25: 745-749.
17. Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997: 26: 122S-127S.
18. Kleter GEM, Brouwer JT, Heijtink RA, Schalm SW, Quint WGT. Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon. Antimicrob Agents Chemother 1993: 37: 595-597.
19. Orito E, Mizokami M, Suzuki K, Ohba Kirn, Ohno T, Mori M, Hayashi K et al. Loss of serum HCV RNA at week 4 of interferon-a therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 1995: 46: 109-115.
20. Hino K, Okuda M, Konishi T, Ishiko H, Okita K. Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-a therapy. Dig Dis Sei 1995: 40: 14-20.
21. Kakumu S, Aiyama T, Okumura A, Iwata K, Ishikawa T, Yoshiowa K. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C. J Gastroenterol Hepatol 1997: 12: 468-472.
22. Manesis EK, Papaioannou C, Gioustozi A, Kafiri G, Koskinas J, Hadziyannis SJ. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alpha-2b for 6 or 12 months: A 4-year follow-up of 211 patients. Hepatology 1997: 26: 734-739.
23. Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S et al. Significance of early measurement of serum hepatitis C virus RNA in predicting response to interferon therapy in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1997: 9: 245-249.
24. Nomura H, Kimura Y, Rikimaru N, Tda H, Okamoto O, Shiraishi G, Kashiwagi SJ. Usefulness of HCV-RNA assays in efficacy evaluation of interferon treatment for chronic hepatitis C: Amplicor HCV assay and branched DNA probe assay. J Infect 1997: 34: 249-255.
25. Karino Y, Toyota J, Sugawara M, Higashino K, Sato T, Ohmura T et al. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. Am J Gastroenterol 1997: 92: 61-65.
26. Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during interferon alpha 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison. Hepatology 1997: 26: 1640-1645.
27. Wada M, Kang KB, Nishigami T, Shimoyama T. Importance of pretreatment viral load and monitoring of serum hepatitis C virus RNA in predicting responses to interferon-cr2a treatment of chronic hepatitis C. J Interferon Cytokine Res 1997: 17: 707-712.
28. Zeuzem S, Leem JH, Franke A, Rüster B, Prümmer O, Herrmann G et ai. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alpha. Hepatology 1998:27: 1149-1156.
29. Kagawa T, Hosoi K, Takashimizu S, Kawazoe K, Mochizuki K, Wasada M et al. Comparison of two interferon alpha treatment regimens characterized by an early virological response in patients with chronic hepatitis C. Am J Gastroenterol 1998: 93: 192-196.
30. Izopet J, Payen JL, Alric L, Sandres K, Charlet JP, Vinel JP et al. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy. J Med Virol 1998: 54: 86-91.
31. Lee WM, Reddy KR, Tong MJ, Black M, van Leeuwen DJ, Hoi-linger FB et al. Early hepatitis C virus-RNA réponses predict interferon treatment outcomes in chronic hepatitis C. Hepatology 1998:28: 1411-1415.
32. Bromver JT, Hansen BE, Niesters HGM, Schalm SW. Early prediction of response in interferon monotherapy and in interferonribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 1999: 30: 192-198.
33. McHutchison J, Blatt L, Sedghi-Vaziri A, Rusell J, Schmid P, Conrad A. Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection? J Hepatol 1998: 29: 362-368.
34. Bellobuono A, Mondazzi L, Tempini S, Chiodo F, Magliano E, Mondini C et al. Should patients with early loss of serum HCVRNA during alpha interferon therapy for chronic hepatitis C be treated for 6 or 12 months? J Hepatol 1999: 30: 8-13.
35. National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C. Hepatology 1997: 26: 2S-10S.
36. Davis GL, Lindsay K, Albrecht J, Bodenheimer HC, Baiart LA, Perrillo RP et al. Clinical predictors of response to recombinant interferon-or treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). J Viral Hepat 1994: 1: 55-63.
37. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998: 339: 1485-1492.
38. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GSM, Ideo G et al. Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon or2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998: 352: 1426-1432.
39. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998: 339: 1493-1499.
40. Castro FJ, Esteban JI, Sauleda S, Viladomiu LI, Bove M, Carbonell J et al. Utility of HCV viremia as a predictive factor of sustained response during interferon or combination therapy. Hepatology 1998: 28, Pt. 2. (Abstract).
41. Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon a-2b with and without ribavirin for chronic hepatitis C. Lancet 1998: 351: 83-87.